I am a medical oncologist who specializes in the treatment of malignancies of the gastrointestinal tract, including esophageal, stomach, colorectal, and pancreatic cancers. My research focuses on the development of new treatments for patients with esophageal and gastric cancers. I am particularly interested in exploring the combination of chemotherapy and radiation to treat cancers of the esophagus. I am also investigating the role that the immune system plays in controlling cancers of the esophagus and stomach to determine if we can harness the immune system to attack these cancers.
Read more Read less
In addition to my work at Memorial Sloan Kettering, I am a member of the Noncolorectal Gastrointestinal Cancer Track for the Scientific Program Committee of the American Society of Clinical Oncology. I am privileged to serve as the Track Leader for 2015–2016.
- Clinical Expertise: Gastrointestinal Malignancies; New Chemotherapies; Esophageal and Gastric Cancers
- Languages Spoken: English
- Education: MD, University of Pennsylvania
- Residencies: Internal Medicine - New York Presbyterian/Weill Cornell Medical Center
- Fellowships: Medical Oncology - Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Read more Read less
Clinical Trials Led by Geoffrey Y. Ku
- A Phase I Study of Crenolanib Added to Ramucirumab/Paclitaxel Therapy for Advanced Stomach and Esophageal Cancers
- A Phase I Study of PRS-343 Immunotherapy for HER2-Positive Cancers, including Esophageal and Gastric Cancers
- A Phase I/II Study of Durvalumab and Chemoradiation before Surgery for Esophageal Cancer
- A Phase II Study of Combination Immunotherapy in Patients with Advanced Stomach Cancer
- A Phase II Study of Tremelimumab and Durvalumab Given Together in Patients with Metastatic or Recurrent Gastric or Gastroesophageal Junction Cancer
Clinical Trials Co-Investigated by Geoffrey Y. Ku
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more